A Phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies

M. S. Blumenreich, T. M. Woodcock, Stephen P Richman, M. K. Jones, P. S. Gentile, T. T. Kubota, J. C. Allegra

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered continuously for 5 days, utilizing a central venous line and a perfusion pump. The starting dose was 0.1 mg/m2/24 hours x 5 days (total dose, 0.5 mg/m2) and was escalated according to a modified Fibonacci scale to 0.2, 0.33, and 0.5 mg/m2/24 hours x 5 days, respectively. Three, three, four, and eight patients were entered, respectively, in each dose level. Toxicities observed were: leukopenia in four patients (nadir leukocyte count <1000 cells/mm3 in one patient and 2000-3000 cells/mm3 in 3 patients); thrombocytopenia, with nadir platelet counts between 50,000 and 100,000 platelets/mm3 in 2 patients; stomatitis in four patients; and nausea in three patients. Vomiting was not observed during the infusions. Two patients may have had a radiation recall phenomenon. Blood count depression, nausea, and mucositis were transient, resolving after a few days. One patient at level IV died of sepsis, which was diagnosed on the fourth day of the infusion, before leukopenia intervened. No objective responses were seen. It was concluded that a higher dose of Act D can be given by continuous infusion than by a bolus injection; the authors recommended 0.5 mg/m2/day x 5 days (total dose, 2.5 mg/m2) for further studies.

Original languageEnglish
Pages (from-to)256-258
Number of pages3
JournalCancer
Volume56
Issue number2
DOIs
StatePublished - Sep 25 1985
Externally publishedYes

Fingerprint

Dactinomycin
Intravenous Infusions
Neoplasms
Leukopenia
Nausea
Karnofsky Performance Status
Infusion Pumps
Stomatitis
Mucositis
Platelet Count
Leukocyte Count
Thrombocytopenia
Vomiting
Sepsis
Blood Platelets
Radiation
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A Phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies. / Blumenreich, M. S.; Woodcock, T. M.; Richman, Stephen P; Jones, M. K.; Gentile, P. S.; Kubota, T. T.; Allegra, J. C.

In: Cancer, Vol. 56, No. 2, 25.09.1985, p. 256-258.

Research output: Contribution to journalArticle

Blumenreich, M. S. ; Woodcock, T. M. ; Richman, Stephen P ; Jones, M. K. ; Gentile, P. S. ; Kubota, T. T. ; Allegra, J. C. / A Phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies. In: Cancer. 1985 ; Vol. 56, No. 2. pp. 256-258.
@article{f9472fd972874412ac0832e9ac724e2c,
title = "A Phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies",
abstract = "Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered continuously for 5 days, utilizing a central venous line and a perfusion pump. The starting dose was 0.1 mg/m2/24 hours x 5 days (total dose, 0.5 mg/m2) and was escalated according to a modified Fibonacci scale to 0.2, 0.33, and 0.5 mg/m2/24 hours x 5 days, respectively. Three, three, four, and eight patients were entered, respectively, in each dose level. Toxicities observed were: leukopenia in four patients (nadir leukocyte count <1000 cells/mm3 in one patient and 2000-3000 cells/mm3 in 3 patients); thrombocytopenia, with nadir platelet counts between 50,000 and 100,000 platelets/mm3 in 2 patients; stomatitis in four patients; and nausea in three patients. Vomiting was not observed during the infusions. Two patients may have had a radiation recall phenomenon. Blood count depression, nausea, and mucositis were transient, resolving after a few days. One patient at level IV died of sepsis, which was diagnosed on the fourth day of the infusion, before leukopenia intervened. No objective responses were seen. It was concluded that a higher dose of Act D can be given by continuous infusion than by a bolus injection; the authors recommended 0.5 mg/m2/day x 5 days (total dose, 2.5 mg/m2) for further studies.",
author = "Blumenreich, {M. S.} and Woodcock, {T. M.} and Richman, {Stephen P} and Jones, {M. K.} and Gentile, {P. S.} and Kubota, {T. T.} and Allegra, {J. C.}",
year = "1985",
month = "9",
day = "25",
doi = "10.1002/1097-0142(19850715)56:2<256::AID-CNCR2820560208>3.0.CO;2-D",
language = "English",
volume = "56",
pages = "256--258",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - A Phase I trial of dactinomycin intravenous infusion in patients with advanced malignancies

AU - Blumenreich, M. S.

AU - Woodcock, T. M.

AU - Richman, Stephen P

AU - Jones, M. K.

AU - Gentile, P. S.

AU - Kubota, T. T.

AU - Allegra, J. C.

PY - 1985/9/25

Y1 - 1985/9/25

N2 - Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered continuously for 5 days, utilizing a central venous line and a perfusion pump. The starting dose was 0.1 mg/m2/24 hours x 5 days (total dose, 0.5 mg/m2) and was escalated according to a modified Fibonacci scale to 0.2, 0.33, and 0.5 mg/m2/24 hours x 5 days, respectively. Three, three, four, and eight patients were entered, respectively, in each dose level. Toxicities observed were: leukopenia in four patients (nadir leukocyte count <1000 cells/mm3 in one patient and 2000-3000 cells/mm3 in 3 patients); thrombocytopenia, with nadir platelet counts between 50,000 and 100,000 platelets/mm3 in 2 patients; stomatitis in four patients; and nausea in three patients. Vomiting was not observed during the infusions. Two patients may have had a radiation recall phenomenon. Blood count depression, nausea, and mucositis were transient, resolving after a few days. One patient at level IV died of sepsis, which was diagnosed on the fourth day of the infusion, before leukopenia intervened. No objective responses were seen. It was concluded that a higher dose of Act D can be given by continuous infusion than by a bolus injection; the authors recommended 0.5 mg/m2/day x 5 days (total dose, 2.5 mg/m2) for further studies.

AB - Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-90) on the Karnofsky scale. Act D was administered continuously for 5 days, utilizing a central venous line and a perfusion pump. The starting dose was 0.1 mg/m2/24 hours x 5 days (total dose, 0.5 mg/m2) and was escalated according to a modified Fibonacci scale to 0.2, 0.33, and 0.5 mg/m2/24 hours x 5 days, respectively. Three, three, four, and eight patients were entered, respectively, in each dose level. Toxicities observed were: leukopenia in four patients (nadir leukocyte count <1000 cells/mm3 in one patient and 2000-3000 cells/mm3 in 3 patients); thrombocytopenia, with nadir platelet counts between 50,000 and 100,000 platelets/mm3 in 2 patients; stomatitis in four patients; and nausea in three patients. Vomiting was not observed during the infusions. Two patients may have had a radiation recall phenomenon. Blood count depression, nausea, and mucositis were transient, resolving after a few days. One patient at level IV died of sepsis, which was diagnosed on the fourth day of the infusion, before leukopenia intervened. No objective responses were seen. It was concluded that a higher dose of Act D can be given by continuous infusion than by a bolus injection; the authors recommended 0.5 mg/m2/day x 5 days (total dose, 2.5 mg/m2) for further studies.

UR - http://www.scopus.com/inward/record.url?scp=0021796990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021796990&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19850715)56:2<256::AID-CNCR2820560208>3.0.CO;2-D

DO - 10.1002/1097-0142(19850715)56:2<256::AID-CNCR2820560208>3.0.CO;2-D

M3 - Article

VL - 56

SP - 256

EP - 258

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -